HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer
Human epidermal growth factor receptor 3 (HER3) is the only family member of the EGRF/HER family of receptor tyrosine kinases that lacks an active kinase domain (KD), which makes it an obligate binding partner with other receptors for its oncogenic role. When HER3 is activated in a ligand-dependent...
Main Author: | Avisek Majumder |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/21/2517 |
Similar Items
-
In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474
by: Priyanka Bapat, et al.
Published: (2021-04-01) -
Targeting the epidermal growth factor receptor (EGFR) - a new therapeutic option in oncology?
by: C Mamot
Published: (2006-01-01) -
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
by: Benjamina Esapa, et al.
Published: (2023-03-01) -
Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01) -
Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
by: Hyun Jung Kim, et al.
Published: (2020-05-01)